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Abstract
Background: Bordetella bronchiseptica is a bacterial respiratory pathogen that infects a broad range
of mammals, causing chronic and often subclinical infections. Gene expression in Bordetella is
regulated by a two-component sensory transduction system, BvgAS, which controls the expression
of a spectrum of phenotypic phases transitioning between a virulent (Bvg+) phase and a non-virulent
(Bvg-) phase.
Results:  Based on the genomic sequence and using the freely available software
ArrayOligoSelector, a long oligonucleotide B. bronchiseptica microarray was designed and
assembled. This long-oligonucleotide microarray was subsequently tested and validated by
comparing changes in the global expression profiles between B. bronchiseptica RB50 and its Bvg-
phase-locked derivative, RB54. Data from this microarray analysis revealed 1,668 Bvg-regulated
genes, which greatly expands the BvgAS regulon defined in previous reports. For previously
reported Bvg-regulated transcripts, the gene expression data presented here is congruent with
prior findings. Additionally, quantitative real-time PCR data provided an independent verification of
the microarray expression values.
Conclusion: The results presented here provide a comprehensive, genome-wide portrait of
transcripts encompassing the BvgAS regulon, while also providing data validating the long-
oligonucleotide microarray described here for studying gene expression in Bordetella bronchiseptica.
Background
Bordetellae are Gram negative bacterial respiratory patho-
gens. Bordetella pertussis and Bordetella parapertussishu, the
causative agents of whooping cough, are human-adapted
variants of Bordetella bronchiseptica, which naturally infects
a broad range of mammals causing chronic and often
asymptomatic infections [1]. The majority of gene expres-
sion in Bordetella is regulated by a two-component sensory
transduction system encoded by the bvg locus. The bvg
locus comprises a histidine kinase sensor protein, BvgS,
and a DNA-binding response-regulator protein, BvgA. In
response to environmental cues, BvgAS controls expres-
sion of a spectrum of phenotypic phases transitioning
between a virulent (Bvg+) phase and a non-virulent (Bvg-
) phase. During the virulent Bvg+ phase, the BvgAS system
is fully active and many of the known virulence factors are
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expressed, such as filamentous hemagglutinin (FHA),
pertactin, fimbriae, adenylate cyclase-hemolysin toxin,
and dermonecrotic toxin (DNT), as well as a type III secre-
tion system (TTSS) in B. bronchiseptica [2]. Conversely,
BvgAS is inactive during the Bvg- phase, resulting in the
maximal expression of motility loci, virulence-repressed
genes (vrg genes), genes required for the production of
urease, and in B. bronchiseptica RB50, a siderophore, alca-
ligin [3-5]. Previous studies involving phase-locked and
ectopic expression mutants demonstrated that the Bvg+
phase promotes respiratory tract colonization by B. pertus-
sis and B. bronchiseptica [6-9], while the Bvg- phase of B.
bronchiseptica  promotes survival under conditions of
nutrient deprivation [6,10].
The signals that activate BvgAS in nature are unknown.
However, in the laboratory, BvgAS is active when the bac-
teria are grown at 37°C and inactive when grown at tem-
peratures below ~26°C or in medium containing MgSO4
or nicotinic acid at concentrations in the millimolar
range. Although originally identified as a positive regula-
tor of virulence gene transcription [11], it is now known
that BvgAS controls expression of over a hundred different
genes whose products are either proven or predicted to
participate in a wide variety of cellular activities including
many basic physiological functions [12-14]. Additionally,
it is now understood that rather than functioning like an
ON/OFF switch, BvgAS functions more like a "rheostat"
capable of controlling gene expression of many pheno-
typic phases in response to subtle differences in environ-
mental conditions [10].
The advent of microarray technology has enabled scien-
tists to investigate biological questions, such as those per-
taining to bacterial pathogenesis and host-pathogen
interactions, in a global fashion. The cDNA microarray
represents a popular array type in which double-stranded
PCR products are spotted onto glass slides. However, con-
struction of such microarrays presents a number of chal-
lenges, largely related to costs associated with amplicon
validation, tracking and maintenance. For example, the
laborious and problematic tracking of PCR amplicons
leads to an estimated 10–30% misidentification [15].
Another limitation of cDNA microarrays is their inability,
due to cross-hybridization, to reliably discriminate
expression patterns of homologous genes [16]. With oli-
gonucleotide arrays, problems related to clone tracking,
homologous gene discrimination, and failed PCR ampli-
cons are avoided, thus making long-oligonucleotide
microarrays a more cost- and management- efficient alter-
native to cDNA microarrays. Here we present the design
and assembly of a long-oligonucleotide B. bronchiseptica
gene-specific microarray using the currently available
genomic sequence generated by the Sanger Institute [17]
and the software package ArrayOligoSelector [18]. This
long-oligonucleotide microarray was then tested and val-
idated by evaluating changes in the global expression pro-
files between B. bronchiseptica strain RB50 and its Bvg-
phase-locked derivative, RB54.
Results and discussion
To construct a B. bronchiseptica-specific whole genome
microarray, the freely available software program, Array-
OligoSelector (AOS) [18], was used to generate 70-mer
oligonucleotide probes for every ORF in the Bordetella
bronchiseptica  RB50 genome [17]. The rationale behind
designing and utilizing oligonucleotide probes versus
PCR amplicons as probes, and subsequently the 70-mer
length of the oligonucleotide probes, was chosen for sev-
eral reasons. Long oligonucleotides are a highly sensitive
alternative to PCR products and provide a means to read-
ily distinguish between genes with high degrees of
sequence similarity, which is an issue for the B. bronchisep-
tica genome [17]. For example, except for the extreme 5'
and 3' termini, the fhaB and fhaS genes are nearly identical
[19]. Additionally, previous results involving an anchored
set of oligonucleotides revealed a strong relationship
between the oligonucleotide length and hybridization
performance [18].
For each B. bronchiseptica ORF, the AOS program opti-
mizes the oligonucleotide selection on the basis of
uniqueness in the genome, sequence complexity, lack of
self-binding and GC content. Candidate oligos closest to
the 3' end of the gene are then chosen [18]. There are a
number of missing array elements due to gene duplica-
tions, prophage duplications, and ORF assignments miss-
ing from the completed genome annotation [17]. These
missing array elements and, in the case of gene duplica-
tions, their corresponding represented array elements are
listed in Additional File 1- see Supplementary Table S1. A
list of the final 4975 oligonucleotide array elements or
probes representing the entire B. bronchiseptica genome is
given in Additional File 1- see Supplementary Table S2.
To test the usefulness of the newly constructed long-oligo-
nucleotide  Bordetella bronchiseptica microarray, a direct
comparison between the transcriptional profile of B. bron-
chiseptica RB50 and RB54, a B. bronchiseptica Bvg- phase
locked derivative of RB50, was performed. The rationale
behind performing this comparison to validate and test
the  B. bronchiseptica long-oligonucleotide microarray is
that this comparison will globally identify B. bronchisep-
tica genes regulated by BvgAS. Previous studies, including
cDNA microarray studies, have identified 538 genes con-
trolled by BvgAS [2,13,14], thus providing a substantial
reportable reference set to validate gene expression data
generated from the newly constructed B. bronchiseptica
long-oligonucleotide microarray.BMC Genomics 2007, 8:220 http://www.biomedcentral.com/1471-2164/8/220
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Utilizing the B. bronchiseptica long-oligonucleotide micro-
array, ratio data collected from microarray analysis involv-
ing the direct comparison between B. bronchiseptica RB50
and RB54 revealed 1,668 Bvg-regulated genes (identified
using SAM with a false discovery rate of <0.1%). This is a
substantial increase in the number of Bvg-regulated tran-
scripts compared to the 538 Bvg-regulated genes recently
reported by others using cDNA microarray analysis [14].
A complete list of the fold-change expression values from
this comparison, along with dye swap experimental data,
is provided in Additional File 1- Supplementary Table S3.
One possible effect of using the B. bronchiseptica RB50
strain grown at 37°C to represent the Bvg+ phase, as
opposed to using a Bvg+ phase-locked strain, is that some
Bvg-activated genes could be missed in this analysis. Pos-
sible explanations for the large increase in Bvg-regulated
transcripts detected in this study, compared to previous
reports, may include (i) differences between strains used,
for example wild-type versus phase-locked derivatives, (ii)
differences between gene expression threshold cut-off val-
ues used in analysis, and (iii) for microarray studies, dif-
ferences between array platforms, such as cDNA
microarrays versus oligonucleotide microarrays. Gene
expression profiles reported here of demonstrated Bvg-
regulated transcripts are consistent with previous results
(Figure 1).
Historically, numerous Bvg-activated genes have been
described, such as TTSS genes, fimbrial genes, filamentous
hemagglutinin, pertactin, adenylate cyclase-hemolysin
toxin, and dermonecrotic toxin [2]. Using the newly con-
structed oligonucleotide B. bronchiseptica microarray, all
of these transcripts were found to be positively regulated
by BvgAS (Figure 1). Along with other virulence-related
transcripts classically characterized as Bvg-activated, three
putative adhesion genes fhaS (+10.37-fold), fhaL (+8.04-
fold), and BB0110 (+8.58-fold) were found to be highly
Bvg-activated, as well as a putative novel toxin, BB3242
(+50.72-fold), containing an aerolysin and pertussis toxin
domain (Table 1 and see Additional File 1- Supplemen-
tary Table S3). Seven ATP-binding cassette (ABC) trans-
porters were found to be Bvg-activated, including BB1593
(+83-fold) (Table 1 and see Additional File 1- Supplemen-
tary Table S3). In other bacteria, these transporters serve as
important virulence factors based upon their role in nutri-
ent uptake and in secretion of toxins and antimicrobial
agents [20]. Five autotransporters were highly Bvg-acti-
vated, including two virulence-associated transcripts vag8
and sphB1 (Table 1 and see Additional File 1- Supplemen-
tary Table S3). The autotransporter sphB1 has been impli-
cated in the maturation process of FHA [21]. The Bvg-
activated expression profile of these transporters impli-
cates their importance in pathogenesis. Five genes
involved in protein folding and ushering were highly Bvg-
activated. These include dsbG  (+35.29-fold) and mucD
Expression of demonstrated Bvg-regulated genes Figure 1
Expression of demonstrated Bvg-regulated genes. 
Hierarchical clustering of known B. bronchiseptica Bvg-regu-
lated genes performed using MeV [32]. Expression profiles of 
genes are in rows. Data are mean centered for each array 
element and averaged from biological replicates. Red, indi-
cates increased expression in RB50; green, decreased gene 
expression in RB50 (and increased expression in RB54); 
black, no significant change in gene expression.
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(+2.75-fold), a DegP family serine protease (Table 1 and
see Additional File 1- Supplementary Table 3). Homo-
logues of both dsbG and mucD are known to serve roles in
virulence in other organisms [22,23]. Twenty-seven tran-
scripts identified as serving roles in global regulatory func-
tions were found to be Bvg-activated, including the
conventionally characterized bvgAS and the TTSS regula-
tor brpL (Table 1 and see Additional File 1- Supplementary
Table S3). Other Bvg-activated transcripts in this group
include the other TTSS regulators (BB1645, BB1646, and
BB1642), three proposed two-component response regu-
latory proteins, and numerous proposed transcriptional
regulators. Lastly, BB4228 (+15.70-fold), recently desig-
nated BopC and characterized as a novel type-III secretion
effector [24], was found to be highly Bvg-activated.
The overall global transcriptional program observed dur-
ing the Bvg- phase supports previous data implicating a
crucial role for the Bvg-phase in survival during environ-
mental stress conditions [2,25]. Genes annotated to serve
global regulatory functions were one of the functional cat-
egories with the highest number of Bvg-repressed tran-
scripts. Transcripts in this category include forty-nine
transcription factors and/or DNA-binding proteins, and
ten two-component systems (Table 2 and see Additional
File 1- Supplementary Table 3). Numerous genes involved
in transport were identified as Bvg-repressed, including
twenty-seven ABC transporters and TonB-dependent
receptors, such as bfrG  BB1294 (-2.86-fold) and bfeA
BB1942 (-2.80-fold) (Table 2 and see Additional File 1-
Supplementary Table S3). As mentioned earlier, these
transporters serve important biological roles in other
organisms, including participation in host-pathogen
interactions as known virulence factors [20]. The Bvg-
repressed expression profile of these genes highlights
nutrient scavenging as a critical ability during Bvg- growth
and supports prior data demonstrating that the Bvg- phase
is optimized for growth under nutrient limiting condi-
tions [2,25].
Consistent with previous results, genes required for the
expression of the siderophore alcaligin [26] and urease [5]
were preferentially activated in the Bvg- phase, along with
a putative hemolysin BB1186 (-2.83-fold) (Table 2 and
see Additional File 1- Supplementary Table S3). Also con-
sistent with previous reports, all of the genes known to be
involved in chemotaxis, such as cheD (-10.59-fold) and
cheW (-15.21-fold), and motility, such as flgB  (-44.49-
fold) and flgC (-32.10-fold), were Bvg-repressed [3] (Table
2 and see Additional File 1- Supplementary Table S3).
Numerous genes involved in electron transport were Bvg-
repressed along with numerous genes involved in protein
folding and ushering, including a high number of univer-
sal stress proteins, congruent with the Bvg- phase role in
stress survival [6,25] (Table 2 and see Additional File S1-
Supplementary Table S3).
Bordetella pertussis only infects humans and, as mentioned
above, is responsible for causing an acute upper-respira-
tory disease known as whooping cough or pertussis. Due
to its high degree of similarity to B. pertussis and its broad
host range, including animals conveniently used in labo-
ratory studies, B. bronchiseptica is widely used as a model
for Bordetella pathogenesis research. Data arising from the
recent completion of the comparative sequencing of three
different Bordetella strains has revealed a loss or inactiva-
tion of a large number of genes in B. pertussis [17]. Thus an
intriguing question is how many of the B. bronchiseptica
Bvg-regulated genes are intact in B. pertussis. To determine
this, the ORF sequence and oligonucleotide probe
sequence for every Bvg-regulated gene identified in this
study was used to blast the B. pertussis genome sequence.
This analysis resulted in identifying 1172 shared genes
that are Bvg-regulated in B. bronchiseptica (see Additional
File S1- Supplementary Table S4).
Real-time quantitative PCR was performed to provide an
independent assessment of microarray expression meas-
urements for selected genes. Genes were chosen to reflect
the full spectrum of fold-changes identified by microarray
analysis. Specifically, transcripts identified as having little
to no change in gene expression by microarray analysis
and selected for qRT-PCR include BB0057 rpoA, BB4989
dnaA, BB1037, and BB3703 eno (Table 3). Bvg-activated
genes identified by microarray analysis and selected for
qRT-PCR include the TTSS regulatory genes, BB1619
bcrH1 and BB1622 bcrH2 (Table 3). On the polar end of
the Bvg spectrum, genes identified as Bvg-repressed and
selected for qRT-PCR include BB2522 and BB1315, a
putative universal stress protein. Additionally, BB4835
rpoH, sigma-32, identified as Bvg-repressed (-3.09-fold)
was also selected for qRT-PCR analysis since it had not
been identified as Bvg-regulated by previous cDNA micro-
array studies [13,14]. Real-time quantitative PCR analysis
of this gene set provided data consistent with the quanti-
tative measures by microarray analysis, using the newly
constructed B. bronchiseptica oligonucleotide microarray
(r2 = 0.94) (Figure 2). Therefore, this real-time quantita-
tive PCR data provides independent verification of the
microarray results.
Given that BvgAS is the major virulence regulator in Bor-
detella, the information presented in this report should
allow researchers to design future experiments targeting
some newly identified Bvg-regulated genes and study their
role in the pathogenesis of this organism. A recent study
demonstrated that Bordetella bronchiseptica, Bordetella par-
apertussis  and  Bordetella pertussis all contain a higher
number of transcription factors or regulatory elementsBMC Genomics 2007, 8:220 http://www.biomedcentral.com/1471-2164/8/220
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Table 1: Representative Bvg+ phase specific genes identified by microarray analysis.
Function Gene Product Fold-Change ± SEM
Cell Adhesin BB0110 putative adhesion 8.58 ± 3.21
BB1658 fim3 serotype 3 fimbrial subunit precursor 32.47 ± 11.10
BB1936 fhaL adhesion 8.04 ± 1.63
BB2312 fhaS adhesion 10.37 ± 2.76
BB2989 fimD fimbrial adhesion 11.58 ± 3.96
BB2992 fimA fimbrial protein 33.75 ± 13.88
BB2993 fhaB filamentous hemagglutin 11.37 ± 4.55
BB3424 fimbrial protein 8.92 ± 2.64
BB3425 fimN fimbrial subunit protein 11.95 ± 2.06
BB3426 fimX fimbrial protein 8.92 ± 2.64
BB3674 fim2 serotype 2 fimbrial subunit precursor 21.89 ± 11.68
Cell Envelope BB1289 putative integral membrane protein 26.29 ± 8.25
BB1368 putative membrane protein 3.94 ± 0.56
BB3119 putative membrane protein 19.27 ± 2.17
BB3157 putative membrane protein 16.41 ± 5.54
BB4029 putative glycosyl transferase 4.96 ± 0.32
BB4266 putative membrane protein 6.84 ± 0.82
BB4269 putative glycosyl transferase 2.23 ± 0.42
BB4284 putative membrane protein 2.96 ± 0.14
Protein Folding and Ushering BB2320 dsbG thiol:disulfide interchange protein precursor 35.29 ± 9.68
BB2991 fimB chaperone protein 11.20 ± 7.71
BB3749 mucD serine protease; trypsin activity 2.75 ± 0.41
BB3803 putative peptidyl-prolyl cis-trans isomerase 4.65 ± 1.26
Global Regulatory Functions BB0308 putative transcriptional regulator 5.67 ± 0.98
BB1607 putative LysR-family transcriptional regulator 3.37 ± 0.55
BB1638 brpL putative RNA polymerase sigma factor 50.66 ± 15.58
BB1642 putative regulator; catalytic activity 112.16 ± 97.97
BB1645 putative anti-sigma factor; ATP binding 9.46 ± 3.00
BB1646 putative antisigma factor antagonist 18.19 ± 6.08
BB2051 putative regulatory protein 2.24 ± 0.59
BB4374 putative AsnC-family transcriptional regulator 5.78 ± 7.25
Metabolism BB0457 probable enoyl-CoA hydrates; isomerase activity 5.72 ± 1.34
BB0458 probable carboxymuconolactone decarboxylase 3.42 ± 0.79
BB1476 putative gluconate dehydrogenase 2.88 ± 0.51
BB1478 putative carbonic anhydrase precursor 4.05 ± 0.77
BB1640 hypothetical protein; glutamate-cysteine ligase activity 63.92 ± 18.15
BB1644 alr alanine racemase, catabolic 253.96 ± 97.47
BB2658 glutamate decarboxylase 2.78 ± 0.93
BB3783 intracellular PHB depolymerase 3.23 ± 0.78
BB4286 nadC putative nicotinate-nucleotidepyrophosphorylase 32.86 ± 6.48
Periplasmic, Exported, Lipoprotein BB0324 cyaA bifunctional hemolysin-adenylatecyclase precursor 6.73 ± 2.52
BB1280 putative exported protein 73.44 ± 37.80
BB1292 putative exported protein 272.88 ± 93.88
BB1641 putative exported protein 149.05 ± 97.51
BB2398 putative exported protein 6.77 ± 1.38
BB2873 putative membrane protein 26.85 ± 13.90
BB3068 putative exported protein 10.90 ± 3.11
BB3242 putative exported protein 48.75 ± 9.65
BB3302 lipoprotein 5.09 ± 0.63
BB3978 dnt dermonecrotic toxin 8.63 ± 3.61
BB4181 putative lipoprotein 3.40 ± 0.25
BB4285 putative exported protein 49.73 ± 14.04
Transport BB0323 cyaC cyclolysin-activating lysine-acyltransferase 2.70 ± 0.27
BB0325 cyaB cyclolysin secretion ATP-binding protein; ABC transporter 2.10 ± 0.31
BB0326 cyaD cyclolysin secretion protein; transporter activity 3.48 ± 0.51
BB0327 cyaE cyclolysin secretion protein; subtilase activity 3.66 ± 1.57
BB0419 sphB1 autotransporter subtilisn-like protease; substilase activity 59.34 ± 43.26
BB1593 putative ABC transport system, membrane protein 83.60 ± 28.88
BB1643 putative inner membrane transport protein 39.61 ± 16.68
BB1864 vag8 autotransporter 122.00 ± 79.14
BB2270 autotransporter 4.71 ± 2.07
BB3826 bfrD probable TonB-dependent receptor for iron transport 2.68 ± 0.58
BB3993 ompQ outer membrane porin protein OmpQ 24.34 ± 8.07
TTSS BB1616 bopN putative outer protein N 504.05 ± 189.58
BB1620 bopD putative outer protein D 457.16 ± 172.40
BB1624 bscI putative type III secretion protein 226.35 ± 80.58
BB1628 bscN putative ATP synthase in type III secretion 115.85 ± 37.00
BB4228 bopCa hypothetical protein; characterized type III effector 15.70 ± 3.85
DNA microarray analysis was used to measure mRNA levels present in B. bronchiseptica RB50 compared to mRNA levels present in B. bronchiseptica RB54. 
Differences in mRNA levels are listed as mean fold-changes ± standard error. Fold-changes were calculated by averaging the data from three biological sample sets. 
aRecently characterized [24].BMC Genomics 2007, 8:220 http://www.biomedcentral.com/1471-2164/8/220
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Table 2: Representative Bvg- phase specific genes identified by microarray analysis.
Function Gene Product Fold-Change ± SEM
Cell Adhesin BB1186 putative hemolysin, homophilic cell adhesion -2.83 ± 0.18
Cell Envelope BB0141 wbmD putative membrane protein -5.19 ± 0.08
BB2618 flgJ peptidoglycan hydrolase -28.12 ± 0.01
BB2618 lpxB lipid-A-disaccharide synthase; lipid A biosynthesis -6.35 ± 0.02
BB2879 putative membrane protein -6.46 ± 0.02
BB4842 putative outer membrane protein -32.02 ± 0.01
Chemotaxis BB2543 motA chemotaxis protein MotA -26.28 ± 0.02
BB2544 motB chemotaxis protein MotB -17.90 ± 0.02
BB2549 cheR chemotaxis protein methyltransferase -10.43 ± 0.03
BB2552 cheZ chemotaxis protein CheZ; catalytic activity -38.44 ± 0.01
Motility BB2553 flhB flagellar biosynthetic protein FlhB -44.48 ± 0.01
BB2555 flhF flagellar biosynthesis protein; RNA binding -32.10 ± 0.00
BB2559 flgB flagellar basal-body rod protein FlgB; motor activity -44.49 ± 0.01
BB2560 flgC flagellar basal-body rod protein FlgC; motor activity -32.10 ± 0.00
BB2585 fliI flagellum-specific ATP synthase FliI; ATP binding -30.75 ± 0.01
Electron Transport BB1283 cyoA ubiquinol oxidase polypeptide II; copper ion binding -5.11 ± 0.08
BB2800 napA periplasmic nitrate reductase precursor; iron ion binding -11.34 ± 0.01
BB3325 putative ferredoxin; electron transport activity -32.43 ± 0.00
BB3927 putative cytochrome; electron transport activity -5.58 ± 0.01
BB4096 putative oxidoreductase -4.90 ± 0.02
BB4497 cydB cytochrome D ubiquinol oxidase subunit II -6.04 ± 0.02
BB4498 cydA cytochrome D ubiquinol oxidase subunit I -5.40 ± 0.07
BB4945 ivd isovaleryl-CoA dehydrogenase -8.90 ± 0.01
Protein Folding and Ushering BB0979 putative universal stress protein -24.76 ± 0.02
BB2875 universal stress family protein -7.45 ± 0.01
BB3257 fkpB FkbP-type peptidyl-prolyl cis-trans isomerase -4.15 ± 0.01
BB4260 putative universal stress protein -9.29 ± 0.01
Global Regulatory Functions BB0725 putative transcriptional regulator -7.82 ± 0.04
BB1122 two-component system sensor kinase; signal transducer -9.65 ± 0.01
BB1187 putative LuxR-family transcriptional regulator -11.60 ± 0.02
BB2108 probable two-component response regulator -18.08 ± 0.01
BB2323 putative transcriptional regulator -11.03 ± 0.03
BB2540 fliA RNA polymerase sigma factor; flagellar operon -16.05 ± 0.01
BB2542 flhC flagellar transcriptional activator FlhC; DNA binding -31.06 ± 0.01
BB2550 cheB protein-glutamate methylesterase;two-component regulator -18.56 ± 0.02
BB3115 methyl-accepting chemotaxis signal transducer protein -10.74 ± 0.02
BB3866 probable LysR-family transcriptional regulator -7.15 ± 0.02
Metabolism BB0868 mmsA methylmalonate-semialdehyde dehydrogenase -8.72 ± 0.02
BB0978 ggt gamma-glutamyltranspeptidase precursor -35.18 ± 0.02
BB1367 cysG siroheme synthase, heme biosynthesis -8.67 ± 0.01
BB2085 hemC porphobilinogen deaminase; synthase activity -16.39 ± 0.01
BB2147 hemN coproporphyrinogen III oxidase -5.84 ± 0.01
BB4409 hemL glutamate-1-semialdehyde 2,1-aminomutase -13.10 ± 0.01
Transport BB0976 lactate permease family protein -21.29 ± 0.01
BB1174 putative ABC transport proteins; ATP-binding component -5.52 ± 0.03
BB1188 HlyD-family secretion protein; protein transporter activity -6.27 ± 0.05
BB1189 probable ABC transporter -7.56 ± 0.06
BB1191 putative outer membrane protein; transporter activity -13.87 ± 0.02
BB1294 bfrG putative TonB-dependent receptor -2.86 ± 0.03
BB1942 bfeA ferric enterobactin receptor -2.80 ± 0.02
BB2402 putative sulfate transporter -6.92 ± 0.02
BB2433 multidrug resistance protein -4.14 ± 0.03
BB2803 ccmA putative heme export protein; heme transporter activity -12.62 ± 0.01
BB2804 ccmB heme exporter protein B -9.57 ± 0.01
BB2805 ccmC putative heme export protein -13.01 ± 0.01
BB4273 atoE putative short-chain fatty acids transporter -7.49 ± 0.01
BB4495 probable ATP-binding component; ABC transporter -33.13 ± 0.01
DNA microarray analysis was used to measure mRNA levels present in B. bronchiseptica RB50 compared to mRNA levels present in B. bronchiseptica 
RB54. Differences in mRNA levels are listed as mean fold-changes ± standard error. Fold-changes were calculated by averaging the data from three 
biological sample sets.BMC Genomics 2007, 8:220 http://www.biomedcentral.com/1471-2164/8/220
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than the genome size of each strain would predict [27].
The microarray analysis presented here identifies, for the
first time, an additional 138 predicted global regulator
elements as being a part of the BvgAS regulon, which
could be described as a modulon. Moreover, the data indi-
cates that a high number of B. bronchiseptica regulators are
under control, either directly or indirectly, of BvgAS, thus
highlighting an organized hierarchical network, with mul-
tiple layers of control, governing transcriptional regula-
tion in B. bronchiseptica. Distinct phenotypic changes
occurring at each end of the Bvg regulatory continuum
have been described since 1960 [28]. Since then, the
molecular basis underlying these morphological phases
has been directly linked to the coordinate expression of
the BvgAS regulon. The results presented here provide a
comprehensive, genome-wide portrait of transcripts
encompassing the BvgAS regulon, while also providing
data validating the usefulness of utilizing the long-oligo-
nucleotide microarray described here for studying gene
expression in B. bronchiseptica.
Conclusion
Long-oligonucleotide microarrays represent a highly sen-
sitive, cost and management efficient, alternative to cDNA
microarrays. Using the complete Bordetella bronchiseptica
genome sequence and ArrayOligoSelector software, a 70-
mer oligonucleotide Bordetella bronchiseptica microarray
was designed and assembled. This long-oligonucleotide
microarray was then tested and validated by comparing
changes in the global expression profiles between Borde-
tella bronchiseptica RB50 and its Bvg- phase-locked deriva-
tive, RB54. Data from this microarray analysis revealed
1,668 Bvg-regulated genes, which dramatically increases
Table 3: Fold-changes identified by quantitative real-time PCR.
Gene Product qRT-PCR Microarray
BB0057 rpoA DNA-directed RNA polymerase alpha chain -2.03 ± 0.01 -1.09 ± 0.06
BB0110 putative adhesion 92.47 ± 0.35 8.58 ± 1.21
BB0376 putative membrane protein 6.23 ± 0.45 3.00 ± 0.72
BB0419 sphB1 autotransporter subtilisin-like protease 137.34 ± 6.96 59.34 ± 4.26
BB1037 LysR-family transcriptional regulator -1.24 ± 0.01 -1.07 ± 0.15
BB1315 putative universal stress protein -64.15 ± 0.35 -11.43 ± 0.03
BB1593 putative ABC transport system, membrane protein 1544.59 ± 8.49 83.60 ± 8.88
BB1619 bcrH1 putative regulatory protein 2943.53 ± 16.33 340.10 ± 7.39
BB1622 bcrH2 putative regulatory protein 1532.48 ± 11.25 286.50 ± 9.03
BB2108 probable two-component response regulator -39.21 ± 1.24 -18.08 ± 0.01
BB2147 hemN oxygen-independent coproporphyrinogen III oxidase -23.10 ± 3.33 -5.84 ± 0.01
BB2320 dsbG thiol:disulfide interchange protein precursor 358.29 ± 5.25 35.29 ± 1.68
BB2323 putative transcriptional regulator -21.86 ± 3.46 -11.03 ± 0.01
BB2367 putative regulatory protein; transcription factor activity -11.71 ± 2.15 -2.95 ± 0.11
BB2434 pckG phosphoenolpyruvate carboxykinase (GTP) -12.57 ± 1.46 -2.88 ± 0.04
BB2435 S-adenosylmethionine-dependent methyltransferase -5.10 ± 1.24 -2.76 ± 0.04
BB2522 conserved hypothetical protein -58.35 ± 0.35 -2.82 ± 0.03
BB3447 cysN sulfate adenylyltransferase subunit 1; (ATP) activity -12.50 ± 0.15 -2.00 ± 0.25
BB3703 eno enolase; phosphopyruvate hydratase activity -2.68 ± 0.14 -1.11 ± 0.08
BB4495 probable ATP-binding component of ABC-transporter -30.63 ± 0.15 -33.12 ± 0.01
BB4506 rpoN probable sigma (54) modulation protein -11.66 ± 0.56 -3.38 ± 0.12
BB4835 rpoH RNA polymerase sigma-32 factor -6.33 ± 0.22 -3.09 ± 0.11
BB4989 dnaA chromosomal replication initiator protein 1.94 ± 0.01 1.27 ± 0.19
Quantitative real-time PCR analysis was used to measure mRNA levels present in B. bronchiseptica RB50 compared to mRNA levels present in B. 
bronchiseptica RB54. Differences in mRNA levels detected by both qRT-PCR and Microarray are listed as mean fold-changes ± standard deviation. 
qRT-PCR fold-changes were calculated using the relative quantitative (ΔΔCT) method, as detailed in the Methods, from three biological sample sets.
Comparison of gene expression measurements by micro- array hybridization and quantitative real-time PCR Figure 2
Comparison of gene expression measurements by 
microarray hybridization and quantitative real-time 
PCR. Changes in gene expression were log transformed (in 
base 2), and the real-time qRT-PCR log2 values (y axis) were 
plotted against the microarray data log2 values (x axis). The 
coefficient of determination (R2) is given.
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the number of Bvg-regulated transcripts identified to date.
Additionally, gene expression profiles of previously dem-
onstrated Bvg-regulated transcripts are consistent with
previous results and quantitative real-time PCR data pro-
vided an independent verification of the microarray
expression values. The results presented here provide a
comprehensive, genome-wide portrait of transcripts
encompassing the BvgAS regulon, and provide data vali-
dating the use of the long-oligonucleotide microarray
described here for studying gene expression in Bordetella
bronchiseptica.
Methods
Microarray fabrication
Using ArrayOligoSelector [18], one 70-mer oligonucle-
otide probe was selected to represent each B. bronchiseptica
RB50 ORF [17]. The 70-bp oligonucleotide probes were
synthesized (Illumina, San Diego, CA), resuspended in
3×SSC to a final concentration of 60 pmol/μL, and spot-
ted onto poly-L-lysine-coated microscope slides, using a
BioRobotics Microgrid II microarrayer (Genomic Solu-
tions, Ann Arbor, MI) as described elsewhere [29]. Each
probe was printed three times per slide. All oligonucle-
otide sequences are listed (see Additional File 1- Supple-
mentary Table S2).
Bordetella Culture and RNA Isolation
B. bronchiseptica strain RB50 was isolated from a naturally
infected New Zealand White rabbit [6] and RB54 is a Bvg-
phase-locked derivative of RB50 [10]. B. bronchiseptica
strains were maintained on Bordet-Gengou (BG) agar
(Difco) containing 10% defibrinated sheep blood for
determination of colony morphology and hemolytic
activity. Three independent biological replicates of B.
bronchiseptica RB50 and RB54, picked from well-isolated
colonies on BG plates, were initially grown in Stainer-
Scholte (SS) broth [30] supplemented with 40 μg/mL
streptomycin. To ensure similar inocula and growth phase
among all biological replicates, bacteria were then subcul-
tured at a starting optical density at 600 nm (OD600) of
0.02 into a 250-mL flask containing 50 mL SS broth and
grown at 37°C with shaking at 275 rpm for 24 hours. At
this time the OD600 for the RB50 cultures were approxi-
mately 1 and the OD600  for the RB54 cultures were
approximately 3.5. Total cellular RNA was extracted using
Trizol reagent (Invitrogen, Carlsbad, CA), treated with
RNase-free DNase I (Invitrogen, Carlsbad, CA), and puri-
fied using RNeasy columns (Qiagen, Valencia, CA)
according to manufacturers' recommended protocols.
Preparation of labeled cDNA
A 2-color hybridization format was used for the micro-
array analysis. For each biological replicate, RNA extracted
from B. bronchiseptica RB50 was used to create Cy5-labeled
cDNA and RNA extracted from B. bronchiseptica RB54 was
used to create Cy3-labeled cDNA. Conversely, dye-swap
experiments were performed analogously, in which RNA
extracted from B. bronchiseptica RB50 was used to create
Cy3- labeled cDNA and B. bronchiseptica RB54 was used to
create Cy5- labeled cDNA. Fluorescently-labeled cDNA
copies of the total RNA pool were prepared by direct
incorporation of fluorescent nucleotide analogs during a
first-strand reverse transcription (RT) reaction as follows:
5 μg total RNA and 4.4 μg of random oligonucleotide hex-
amers were incubated 2 minutes at 98°C, cooled on ice,
combined with SuperScript III RTase buffer, 0.5 mM
dATP, dGTP, dCTP, 0.2 mM dTTP, 1.5 nmol Cy3- or Cy5-
dUTP (Amersham), and 2 μL SuperScript III RTase (in a
volume of 26 μL). This mixture was incubated 10 minutes
at 25°C and 120 minutes at 50°C. The two differentially
labeled reactions to be compared were mixed and buffer
exchange, purification, and concentration was accom-
plished by microcon-10 (Amicon) filtration.
Microarray hybridization and data analysis
Oligonucleotide microarrays were first prehybridized for
1 hour in 5×SSC, 1% BSA and 0.1% SDS at 42°C, fol-
lowed by washing with H2O and then with isopropanol
and dried by centrifugation for 5 minutes at 50×g. Follow-
ing prehybridization, 45 μL hybridization solution
(labeled cDNA, 5 μg tRNA, 2×SSC, 25% formamide, 0.1%
SDS) was applied to oligonucleotide microarrays and
incubated in a humidified chamber overnight at 50°C.
Arrays were subsequently removed from humidified
chambers and quickly submerged and washed in 1×SSC
and 0.05% SDS for approximately 2 minutes, followed by
two additional washes for 2 minutes each in fresh
0.06×SSC. Slides were then dried by centrifugation for 5
minutes at 50×g, scanned using a GenePix 4000B micro-
array scanner, and analyzed with GenePix Pro software
(Axon Instruments, Union City, CA). Spots were assessed
visually to identify those of low quality and arrays were
normalized so that the median of ratio across each array
was equal to 1.0. Automatically and manually flagged
spots, spots with the sum of medians (635/532) signal
intensity less than or equal to 100, and spots with signal
intensity below threshold (sum of median intensities plus
one standard deviation above the mean background)
were filtered out prior to analysis. Ratio data from the
three biological replicates were compiled and normalized
based on the total Cy3% intensity and Cy5% intensity to
eliminate slide to slide variation. Gene expression data
were then normalized to 16S rRNA. The statistical signifi-
cance of the gene expression changes observed was
assessed by using the significant analysis of microarrays
(SAM) program [31]. A one-class unpaired SAM analysis
using a false discovery rate of 0.063% (<0.1%) was pre-
formed. Hierarchical clustering of microarray data using
Euclidean Distance metrics and Average Linkage cluster-
ing was performed using MeV software from TIGR [32].BMC Genomics 2007, 8:220 http://www.biomedcentral.com/1471-2164/8/220
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Quantitative real-time PCR
DNase-treated total RNA (1 μg) from each biological rep-
licate was reverse transcribed using 300 ng of random oli-
gonucleotide hexamers and SuperScript III RTase
(Invitrogen, Carlsbad, CA) according to manufacturer's
protocol. The resulting cDNA was diluted 1:1000 and 1 μL
used in quantitative PCR reactions containing 300 nM
primers and 2XSYBR Green PCR Master Mix (Applied Bio-
systems) using an Applied Biosystems 7300 real-time PCR
detection system (Applied Biosystems, Foster City, CA).
Primers were designed using Primer Express software
(Applied Biosystems, Foster City, CA) and are listed in
Additional File 1- Supplementary Table 4. To confirm the
lack of DNA contamination, reactions without reverse
transcriptase were performed. Dissociation curve analysis
was performed for verification of product homogeneity.
Threshold fluorescence was established within the geo-
metric phase of exponential amplification and the cycle of
threshold (Ct) determined for each reaction. The cycle of
threshold (Ct) from all three biological replicates for each
strain (RB50 and RB54) was compiled and the 16S RNA
amplicon was used as an internal control for data normal-
ization. Fold change in transcript level was determined
using the relative quantitative method (ΔΔCT) [33].
Microarray accession numbers
Microarrays have been deposited in ArrayExpress under
accession number E-MEXP-961.
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